NCT06570434View on ClinicalTrials.gov

Phase 1b/2a in SLE With Budoputug

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
Systemic Lupus ErythematosusSLEB Cells
Interventions
DRUG

budoprutug

monoclonal antibody

Sponsors

Lead Sponsor

Tenet Medicines
All Listed Sponsors
lead

Tenet Medicines

INDUSTRY